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Nuclear bodies represent a heterogeneous class of nuclear structures. Herein, we describe that a
subset of nuclear bodies is highly enriched in components of the ubiquitin–proteasome pathway
of proteolysis. We coined the term clastosome (from the Greek klastos, broken and soma, body) to
refer to this type of nuclear body. Clastosomes contain a high concentration of 1) ubiquitin
conjugates, 2) the proteolytically active 20S core and the 19S regulatory complexes of the 26S
proteasome, and 3) protein substrates of the proteasome. Although detected in a variety of cell
types, clastosomes are scarce under normal conditions; however, they become more abundant
when proteasomal activity is stimulated. In contrast, clastosomes disappear when cells are treated
with proteasome inhibitors. Protein substrates of the proteasome that are found concentrated in
clastosomes include the short-lived transcription factors c-Fos and c-Jun, adenovirus E1A pro-
teins, and the PML protein. We propose that clastosomes are sites where proteolysis of a variety
of protein substrates is taking place.
INTRODUCTION
The proteasome is a large proteolytic complex involved in
regulated degradation of intracellular proteins (Coux et al.,
1996; Baumeister et al., 1998; Voges et al., 1999). Short-lived
proteins such as cell cycle regulators and transcription fac-
tors are specifically targeted for proteasome degradation by
the ubiquitin-conjugation pathway. Other substrates for this
pathway include abnormal soluble proteins from the nu-
cleus and the cytosol, and proteins of the endoplasmic re-
ticulum that have been retro-translocated to the cytosol
(Bonifacino and Weissman, 1998). Most protein substrates of
the proteasome are marked by covalent ligation to ubiquitin,
which then acts as a signal to target the modified substrate
for proteolytic degradation.
The ubiquitin signal is generated by a series of dedicated
enzymes that recognize the target proteins (Hershko and
Ciechanover, 1998). Conjugation of ubiquitin involves the
formation of an isopeptide bond between the C-terminal
glycine residue of ubiquitin and the -amino group of a
lysine residue of the target protein. Ubiquitination begins
with an activating enzyme, E1, that hydrolyses ATP and
forms a high-energy thioester between a cysteine of its active
site and the C terminus of ubiquitin. The ligation of ubiq-
uitin to the substrate is then carried out by a complex
composed of a ubiquitin-protein ligase (E3) and a ubiquitin-
conjugating enzyme (E2), with E3 being the major determi-
nant of substrate specificity. Conjugated ubiquitin can be a
substrate for further ubiquitination reactions and, indeed,
most substrates are modified by multiubiquitin chains in
which single ubiquitin molecules are linked via isopeptide
bonds (Thrower et al., 2000).
The proteasome is a 26S multimeric enzyme composed of
two subcomplexes, the 20S proteasome and the 19S regula-
tor (Bochtler et al., 1999; Voges et al., 1999; Zwickl et al., 2000).
The 20S proteasome forms the proteolytic core, whereas the
19S regulator (or PA700) confers ATP dependency and ubi-
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quitinated substrate specificity on the enzyme. Current
models propose a multistep mechanism for protein degra-
dation by the proteasome. The substrate is initially tethered
to the proteasome by specific recognition of its ubiquitin tag;
this is followed by interaction of the substrate with the
regulatory particle, which exhibits chaperone-like activity
and promotes substrate unfolding (Braun et al., 1999); the
unfolded substrate is then translocated through a narrow
channel to gain access to the proteolytic active sites of the
enzyme located within the lumen of the core particle.
Although it has been traditionally thought that multiubiq-
uitin chains are virtually essential to target protein sub-
strates for degradation by the eukaryotic 26S proteasome,
recent work unraveled a class of proteins that can be de-
graded by the proteasome in vivo independently of ubiq-
uitin (Verma and Deshaies, 2000). These include ornithine
decarboxylase and the cyclin-dependent kinase inhibitor
p21Cip1. More recently, the PML protein was shown to be
degraded by the proteasome (Zhu et al., 2001), and whether
this process depends on ubiquitination remains an open
question.
Immunolocalization and biochemical fractionation studies
showed that proteasomes are localized both in the nucleus
and in the cytoplasm of eukaryotic cells (Brooks et al., 2000,
and references therein). In living yeast cells, 26S protea-
somes accumulate predominantly in the nuclear envelope-
endoplasmic reticulum network (Enenkel et al., 1998; Wilkin-
son et al., 1998), and recent data suggest that proteasome
localization at these sites is important for proper function
(Tatebe and Yanagida, 2000). In contrast, green fluorescent
protein-tagged proteasomes appear uniformly distributed
throughout the cytoplasm and the nucleoplasm in live hu-
man cells (Reits et al., 1997). Within these two compartments
proteasomes diffuse rapidly, suggesting that recognition and
degradation of substrates result from random collisions be-
tween the proteasome and intracellular proteins (Reits et al.,
1997). Contrasting with this view, dividing cells show a
preferential concentration of proteasomes around spindle
microtubules (Amsterdam et al., 1993). This pattern is rem-
iniscent of the behavior of cyclin B, which is degraded by the
ubiquitin–proteasome pathway and disappears after a wave
that starts at the spindle poles and spreads to the spindle
equator (Huang and Raff, 1999). This immediately raises the
question of whether association of proteasomes with the
spindle contributes to the spatially regulated disappearance
of cyclin B at the end of mitosis.
During interphase, proteasomes are responsible for the
selective degradation of a number of short-lived nuclear
transcription factors whose activity must be tightly regu-
lated, such as nuclear factor-B, STAT1, and Fos/Jun (Ciec-
hanover et al., 1991; Palombella et al., 1994; Kim and Mania-
tis, 1996). In face of the increasing evidence showing that
compartmentalization of regulatory factors by sequestration
plays a key role in nuclear function, we decided to investi-
gate the subnuclear localization of the 26S proteasome. Our
results show that although proteasomes are most often dif-
fusely distributed throughout the nucleoplasm, they occa-
sionally concentrate in discrete structures. Electron micro-
scopic analysis revealed that these structures correspond to
complex doughnut-shaped nuclear bodies. In addition to
19S and 20S proteasomes, the bodies contain ubiquitin, and
a number of proteasome substrates, including the adenovi-
Figure 1. Mammalian cell nu-
clei contain domains highly en-
riched in proteasomes. Antibod-
ies directed against the 20S
catalytic subunit of the protea-
some were used to perform im-
munofluorescence on a variety
of mammalian cell types. These
included neurosecretory neu-
rons of the supraoptic nucleus
(A), astrocytes (B), and oligoden-
drocytes (C) obtained from
squash preparations of rat hypo-
thalamus, and primary cultures
of Schwann cells prepared from
rat sciatic nerve (D), human fi-
broblasts WI-38 (E), and HeLa
cells (F). Although anti-20S pro-
teasome antibodies label both
nucleus and cytoplasm, staining
of the nucleoplasm is more in-
tense. Note the presence of
brightly labeled intranuclear
structures, of heterogeneous size
and shape. Bar, 10 m.
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ral protein E1A proteins, c-Fos and c-Jun, and PML. The
results further show that proteasome-containing nuclear
bodies are dynamic structures, which assemble transiently
under conditions of high proteolysis in the nucleus. We
propose the name clastosome (from the Greek klastos, broken
and soma, body) to refer to this nuclear domain.
MATERIALS AND METHODS
Cell Culture
HeLa cells (human epitheloid carcinoma, cervix), and WI-38 cells
(human female lung diploid fibroblasts) were grown as monolayers
in minimum essential medium supplemented with 2 mM l-glu-
tamine, 50 IU/ml penicillin, 50 mg/ml streptomycin, and 10% fetal
calf serum (Invitrogen, Carlsbad, CA). Primary cultures of Schwann
cells were prepared as described by Brockes et al. (1979). Briefly,
sciatic nerves were dissected from 3-d-old Sprague-Dawley rats,
and mixed cultures of Schwann cells and endoneurial fibroblasts
were maintained in minimum essential medium supplemented with
10% fetal bovine serum for 1 d. To reduce fibroblast contamination,
the culture was then incubated for 2 d in the presence of 105 M
cytosine arabinose. On the 4th d the cells were transferred to poly-
lysine-coated coverslips and maintained for further 3 d in the pres-
ence of 10% fetal bovine serum, 2 M forskolin, and 20 g/ml
bovine pituitary extract.
Animals
Male, 3-mo-old rats of the Sprague-Dawley strain were kept on a
12-h day, 12-h night lighting regime with lights out at 8:00 AM. All
animals were sacrificed by overdose of pentobarbital. To induce an
osmotic stress, animals were given a single intraperitoneal injection
of 1.5 M NaCl (18 ml/kg), as described previously (Lafarga et al.,
1998).
Immunofluorescence
For indirect immunofluorescence, cultured cells were grown on 10-
 10-mm glass coverslips. The cells were washed twice in phos-
phate-buffered saline (PBS), fixed with 3.7% formaldehyde (freshly
prepared from paraformaldehyde) in PBS for 10 min at room tem-
perature, and subsequently permeabilized with 0.5% Triton X-100 in
PBS for 20 min at room temperature. Rats were perfused through
the ascending aorta with 3.7% formaldehyde in PBS, pH 7.4, for 15
min at room temperature. Supraoptic nuclei were dissected out of
500-m-thick hypothalamic slices. These tissue fragments were
washed in PBS for 1 h and individually transferred to a drop of PBS
on a siliconized slide. Then, a coverslip was applied on top of the
slide and the tissue was squashed by percussion with a histological
needle. The preparation was then frozen in dry ice, and the cover-
slip was removed using a razor blade. The slides with adhered
neurons were sequentially dehydrated in 96 and 70% ethanol at 4°C
for 10 min and rinsed in PBS. Before immunostaining, the samples
were sequentially incubated with 0.5% Triton X-100 in PBS for 10
min, 0.1 M glycine in PBS for 30 min, and 0.01% Tween 20 in PBS for
5 min. For immunolabeling, cells were rinsed in PBS containing
0.05% Tween 20, incubated for 1 h with primary antibodies diluted
in PBS, washed in PBS containing 0.05% Tween 20, and incubated
for 45 min with the appropriate secondary antibodies conjugated to
fluorescein (fluorescein isothiocyanate), or Texas Red (Jackson Im-
munoresearch Laboratories, West Grove, PA). Finally, the cover-
slips were mounted in VectaShield (Vector Laboratories, Peterbor-
ough, United Kingdom) and sealed with nail polish. Confocal
Figure 2. Ubiquitin and proteins degraded by the proteasome colocalize in proteasome-domains. Primary Schwann cells were double-
labeled with antibodies directed against 20S proteasome and c-Jun (A and F), 19S proteasome and c-Jun (B and G), 20S proteasome and c-Fos
(C and H), ubiquitin and c-fos (D and I), and ubiquitin and c-Jun (E and J). (K–O) Overlay of red and green images. Overlapping of red and
green staining produces a yellowish color. Bar, 10 m.
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microscopy was performed with either a laser scanning microscope
(LSM 510; Carl Zeiss, Göttingen, Germany) or an MRC-1024 (Bio-
Rad, Hercules, CA) by using excitation wavelengths of 488 nm (for
fluorescein isothiocyanate) and 543 nm (for Texas Red). Each chan-
nel was recorded independently, and pseudocolor images were
generated and superimposed.
Immunoelectron Microscopy
Immunoelectron microscopy was performed on cultured Schwann
cells or tissue fragments from rat sciatic nerve. Samples were fixed
with 4% formaldehyde (freshly prepared from paraformaldehyde)
in 0.12 M phosphate buffer, pH 7.4, for 20 min at room temperature,
rinsed in phosphate buffer, dehydrated in increasing concentrations
of methanol, and embedded in Lowicryl K4 M at 20°C. Ultrathin
sections on gold grids were sequentially incubated with 0.1 M
glycine in PBS (15 min), 3% bovine serum albumin (BSA) in PBS (15
min), and finally the primary antibody diluted in 1% BSA, 0.1 M
glycin in PBS (1 h at room temperature). After washing, the sections
were incubated with appropriate secondary antibody conjugated to
either 5- or 10-nm gold particles (BioCell, Cardiff, United Kingdom)
diluted 1:25 in 0.1% BSA in PBS (45 min at room temperature).
Finally, the sections were washed and stained with 10% aqueous
uranyl acetate. As controls, sections were treated as described but
omitting the primary antibody. Ultrathin sections were examined
with an EM208 electron microscope (Philips, Eindhoven, the Neth-
erlands) operated at 60 kV.
Antibodies
Proteasomes were detected using polyclonal antibodies directed
against the 20S catalytic core (Arribas et al., 1994; Menqual et al.,
1996), and the 19S regulator ATPase subunit 6b (Tbp7; Affiniti
Research Products, Exeter, United Kingdom). Ubiquitin-conjugates
were labeled with antibody Z 0458 from DAKO (Glostrup, Den-
mark), and PML was detected with monoclonal antibody (mAb)
PG-M3 from Santa Cruz Biotechology (Santa Cruz, CA). Addition-
ally, the following antibodies were used: mAb 3A3 directed against
Hsp70/Hsc70 (MA3-006; Affinity Bioreagents, Golden, CO); mAb
M73 raised against E1A proteins (Harlow et al., 1985); mAb 2G9C3
directed against c-Fos (Oncogene Science, Cambridge, MA); mAb
anti-c-Jun (J31920; Transduction Laboratories, Lexington, KY); poly-
clonal antibodies anti-c-Jun (PC06; Oncogene Science); mAb 4G3
(Euro Diagnostica, The Netherlands) directed against the U2B
snRNP protein (Habets et al., 1989); rabbit polyclonal serum 204.3
anti-coilin (Bohmann et al., 1995); mAb 2B1 anti-SMN (Liu and
Dreyfuss, 1996); and rabbit polyclonal antibody C-20 (sc-333; Santa
Cruz Biotechnology) directed against Sam68 (Chen et al., 1999).
Specificity of antibodies used was confirmed by Western blotting.
Proteolysis Inhibitors
HeLa cells were exposed for 3 h to the proteasomal inhibitors
MG132 (50 M; Calbiochem, San Diego, CA), lactacystin (10 M;
Calbiochem), or the lysosomal protease inhibitor E64 (10 M; Sig-
ma-Aldrich, St. Louis, MO). Each of these compounds was dis-
solved in dimethyl sulfoxide (DMSO), and the final concentration of
DMSO in the culture medium was 0.25%.
Plasmids and Transfections
Plasmid pE1A contains nucleotides 1–1773 of genomic Ad2 se-
quences (pML 005 in Bondesson et al., 1994). Plasmids encoding
human c-Jun (pMT35), human c-Jun with a deletion of the  domain
(pMT140), and chicken v-Jun (pMT59) were described previously
(Treier et al., 1994). HeLa cells were transiently transfected using
Figure 3. Proteasome-enriched domains disappear in the presence of proteasome inhibitors. HeLa cells were either mock treated (A) or
incubated for 3 h in the presence of E64 (B), lactacystin (C), and MG132 (D). The cells depicted in E were allowed to recover for 12 h after
treatment with MG132. All cells were immunolabeled with antibodies directed against the 20S catalytic core of the proteasome. Bar, 10 m.
(F) Proportion of cells containing proteasome-enriched domains and the number of bodies per cell were estimated. After treatment with E64,
the proportion of cells that contain bodies does not significantly differ from the control population. The graph depicts means  SEs (three
separate experiments were performed and a total of 300 cells analyzed for each drug treatment).
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FuGene 6 (Roche Applied Science, Indianapolis, IN), according to
the manufacturer’s instructions.
RESULTS
Mammalian Cell Nuclei Contain Domains Enriched
in Proteasomes, Ubiquitin, and Short-lived
Transcription Factors
To study the subcellular distribution of proteasomes in
mammalian cells, immunofluorescence was performed us-
ing polyclonal antibodies specific for the 20S core catalytic
component of the 26S proteasome. Characterization of these
antibodies was described previously (Arribas et al., 1994;
Mengual et al., 1996).
In agreement with other studies, anti-20S antibodies label
both the nucleus and the cytoplasm with a diffuse pattern.
Similar results were observed in a variety of cell types,
including neurons, astrocytes, and oligodendrocytes from
rat brain, primary cultured rat Schwann cells, primary hu-
man fibroblasts, and HeLa cells. Surprisingly, a fraction of
all cellular populations analyzed contained in addition at
least one brightly labeled discrete structure in the nucleo-
plasm (Figure 1). These structures are heterogeneous in size
and shape, and although they are occasionally observed at
the periphery of the nucleolus, they appear randomly lo-
cated in the interior of the nucleus.
Double-labeling experiments revealed that 20S, 19S pro-
teasomes and ubiquitin-conjugates colocalize in the brightly
labeled nuclear structures (Figure 2). In addition, both c-Jun
and c-Fos (two short-lived transcription factors degraded by
the ubiquitin–proteasome pathway) accumulate in the pro-
teasome-enriched structures. Proteins that concentrate in
discrete nuclear domains but do not colocalize with the
proteasome-enriched structures include coilin (Gall, 2000),
splicing factors (Misteli, 2000), SMN (Liu and Dreyfuss,
1996), and Sam68 (Chen et al., 1999) (our unpublished data).
Proteasome-enriched Nuclear Domains Are Dynamic
Structures
Proteasomal function can be inhibited pharmacologically by
covalent or noncovalent modification of its -subunits. Com-
monly used proteasome inhibitors include peptide alde-
hydes and lactacystin. Peptide aldehydes act by forming a
reversible hemiacetal adduct with Thr1 on catalytically ac-
tive -subunits (Rock et al., 1994; Löwe et al., 1995; Seemüller
et al., 1995), whereas the natural product lactacystin irrevers-
ibly alkylates Thr1 (Omura et al., 1991; Fenteany et al., 1995;
Dick et al., 1996; Groll et al., 1997). To investigate how pro-
teasome inhibitors affect proteasome-enriched nuclear do-
mains, HeLa cells were treated for 12 h with either the
peptide aldehyde MG132; lactacystin; a protease inhibitor
specific for lysosomal cysteine proteases (E64); or the solvent
in which the inhibitors were dissolved (DMSO). Treated
cells were fixed and immunolabeled with anti-20S protea-
some polyclonal antibodies (Figure 3, A–E). The proportion
of cells containing proteasome-enriched domains (or bod-
ies), and the number of bodies present per nucleus was then
estimated (Figure 3F).
Incubation with MG132 caused a dramatic disappearance
of proteasome-enriched bodies, compared with control cells
treated with either solvent only or E64 (a protease inhibitor
that does not interfere with proteasome activity). Because
MG132 causes a reversible inhibition of the proteasome, cells
treated with this peptide for 12 h were washed and allowed
to recover for 12 h. After this recovery period, the proportion
of cells containing at least one body was similar to that
observed in control cells, but the number of bodies per
nucleus was higher. Thus, inhibition of proteasomal func-
tion induces the disassembly of proteasome-containing nu-
clear domains, whereas withdrawal of the inhibition leads to
reassembly of these structures. The higher number of bodies
observed after inhibitor withdrawal may be the result of
increased proteasomal activity on proteins targeted for deg-
radation that accumulated during the period of treatment
with the inhibitor.
If the assembly of proteasome-enriched bodies depends
on proteasomal activity, it is expected that increasing the
cellular levels of proteasome substrates should stimulate the
formation of these structures. We therefore thought to esti-
mate the number of bodies in cells under conditions that are
known to trigger proteasome-dependent protein degrada-
tion.
Transient expression of immediate-early genes such as
c-fos is highly inducible as a result of a specific response to
growth factors or serum (Bravo et al., 1986). This prompted
us to investigate the distribution of proteasomes in response
to serum stimulation of cultured cells. Primary human fi-
broblasts (WI38) were cultured in the presence of 0.1% fetal
calf serum for 4 d, transferred to fresh medium containing
20% serum, and analyzed 3 h later. In clear contrast with
unstimulated cells, which were largely devoid of protea-
some-containing bodies (our unpublished data), cells incu-
bated with serum for 3 h contained one or more bodies
Figure 4. Serum stimulation of fibroblasts induces the appearance
of proteasome-enriched domains. Primary human fibroblasts (WI-
38) grown in the presence of 0.1% fetal calf serum (FCS) for 4 d were
stimulated for 75 min with 20% FCS. Immunofluorescence was
performed using antibodies directed against 20S proteasome (A) or
19S proteasome (B). Cells were additionally double-labeled with
anti-20S proteasome and anti-Hsp70/Hsc70 antibodies (C and D).
Bar, 10 m.
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(Figure 4, A–D). As depicted in Figure 4, C and D, these
nuclear bodies are also labeled by an mAb (3A3) directed
against Hsp70 and Hsc70. Several lines of evidence indicate
that the molecular chaperones Hsp70 and Hsc70 interact
with the proteasome and are required for the degradation of
some proteins (Bercovich et al., 1997; Fischer et al., 1997;
Luders et al., 2000; Verma et al., 2000). In fact, substrate
unfolding is a kinetically dominant step in proteolysis, and
at least certain substrates require extraproteasomal chaper-
ones for efficient degradation (Thrower et al., 2000). Thus,
the finding that chaperones Hsp70/Hsc70 localize in protea-
some-enriched bodies supports the view that these struc-
tures contain functional proteasomes.
It is well established that administration of hypertonic
NaCl solutions by intraperitoneal injection in rats causes
both osmotic and stressful effects (Ceccateli et al., 1989; Sharp
et al., 1991; Xiong and Hatton, 1996). This type of stimulus
evokes a transient expression of immediate-early genes such
as c-fos and c-jun in hypothalamic magnocellular neurose-
cretory neurons (Wang et al., 1997, and references therein).
This is followed by an up-regulated synthesis of antidiuretic
hormone, a major regulator of body fluid balance (Sherman
et al., 1986; Herman et al., 1991; Ding et al., 1994). We have
previously shown that in unstimulated animals, the neuro-
secretory neurons in hypothalamic supraoptic nucleus
(SON) are devoid of Fos immunoreactivity. At 30 min after
hypertonic saline injection, c-Fos is detected in most neuro-
nal nuclei. Expression of Fos is maximal at 2 h after injection,
decreases drastically at 12 h and is no longer detected at 24 h
(Lafarga et al., 1998). Consistent with these results, admin-
istration of hypertonic saline was shown to induce a tran-
sient synthesis of c-fos mRNA in SON neurons, which occurs
within 5 min and peaks at 30–60 min, whereas expression of
Fos protein is maximal at 2 h and decreases thereafter (Sharp
et al., 1991; Xiong and Hatton, 1996). In addition to Fos and
Jun, a number of other stress-induced proteins are likely to
be degraded by the ubiquitin–proteasome pathway in these
cells. We therefore counted the number of proteasome-
containing bodies in SON neurons from control (unstimulated)
animals, and animals sacrificed 3 h after hypertonic saline
injection (i.e., when proteolytic destruction of stress-induced
proteins is high). The results show that at 3 h after injection
there is a drastic increase in the proportion of neurons contain-
ing at least one body, as well as a significant increase in the
number of bodies per nucleus (Figure 5, A–F). Both Fos and Jun
proteins colocalize with 19S and 20S proteasomes in the nu-
clear body (Figure 5, D and E). At 24 h after injection the
number of bodies decreased significantly, although they were
still more abundant than in control cells (Figure 5F).
Additional regulators of proteasomal activity are the ad-
enovirus early region 1 transforming proteins. Adenovirus
E1A interacts with regulatory components of the 19S pro-
teasome and inhibits the degradation of p53 and E2F tran-
scription factors (Hateboer et al., 1996; Nakajima et al., 1998;
Grand et al., 1999; Turnell et al., 2000). Furthermore, E1A is
itself a substrate for proteasomal-mediated degradation
(Turnell et al., 2000). After transient expression of E1A in
HeLa cells, the protein appears exclusively localized in the
nucleoplasm with higher concentration in structures of ir-
regular shape and size (Figure 6, A and D). Double-labeling
experiments indicate that E1A, proteasomes, and ubiquitin
colocalize in the same structures (Figure 6, A–F). Although
the proportion of cells containing labeled nuclear bodies is
not significantly affected by E1A expression, cells transfected
with E1A have more bodies per nucleus than cells that were
either nontransfected (Figure 6G) or transfected with control
plasmids (our unpublished data). Noteworthy, colocaliza-
tion of E1A with proteasome and ubiquitin is not complete.
There are nuclear bodies labeled by proteasome or ubiquitin
antibodies that do not contain E1A (Figure 6E, arrow), and
E1A proteins do not always occupy the entire proteasome/
ubiquitin-enriched structure (Figure 6F, arrow).
In summary, our data show that the proteasome-en-
riched nuclear domains contain proteins that are either
proteasome substrates or interact with proteasome com-
ponents. These nuclear domains or bodies disappear
Figure 5. Stress induces the formation of
proteasome-enriched domains in rat brain
neurons. Hypotalamic neurosecretory
neurons were obtained from control ani-
mals (A and B) and animals sacrificed 3 h
after intraperitoneal injection of an hyper-
tonic saline solution to induce osmotic
stress (C–E). Cells were immunolabeled
with antibodies directed against 20S pro-
teasome (A and C) or 19S proteasome (B).
Cells were additionally double-labeled
with either anti-19S proteasome (D, red
staining) and anti-c-Fos antibodies (D,
green staining), or anti-19S proteasome (E,
red staining) and anti-c-Jun antibodies (E,
green staining). (D and E) Overlay of red
and green images; colocalization produces
a yellowish color. Bar, 10 m. (F) Propor-
tion of neurons containing proteasome-en-
riched domains and the number of bodies
per cell were estimated at 0, 3, and 24 h
after saline injection. The graph depicts
means  SEs (for each time point four
animals were sacrificed, and from each
animal 150 neurons were analyzed).
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when cells are treated with proteasome inhibitors and
they form transiently in response to an up-regulation of
proteasome activity in the nucleus. Taken together, the
data suggest that these structures represent sites where
proteasome-dependent proteolysis is taking place. We
will refer to them as clastosomes.
Viewed with the Electron Microscope, Clastosomes
Correspond to Complex Nuclear Bodies
Anti-20S proteasome and anti-c-Jun antibodies were used to
perform immunoelectron microscopy on ultrathin sections
of rat brain neurons. As depicted in Figure 7, immunogold
particles specifically decorate defined subnuclear structures.
These are elongated structures with 0.2–0.5 m in diameter
and 0.5–0.9 m in length. In cross sections these structures
present a characteristic ring-like or doughnut-shaped pro-
file, and occasionally they appear in pairs (Figure 7, A and
D). Although no obvious links to nucleoli, chromatin, or any
other subnuclear compartment were detected, the protea-
some-containing structures are often found in proximity to a
nucleolus. On the basis of these morphological features, the
proteasome-containing structures correspond to the so-
called complex nuclear bodies characterized by the presence
of a ring-like “capsule” surrounding a central core with
heterogeneous content (Bouteille et al., 1974).
Clastosomes Contain PML
Immunoelectron microscopic analysis with anti-PML anti-
bodies has revealed that nuclear bodies associated with this
protein are shaped like a doughnut (Zhong et al., 2000).
Given this morphological similarity with clastosomes, we
performed double-labeling experiments with anti-PML and
either anti-proteasome or anti-ubiquitin antibodies. As illus-
trated in Figure 8, PML is detected in clastosomes. As ob-
served with E1A proteins (Figure 6), this colocalization is
not always perfect. PML tends to occupy only part of a
clastosome, indicating that other components are present in
the structure. Furthermore, several PML bodies do not stain
with proteasome or ubiquitin antibodies. In good agreement
with these data, it was reported that at the electron micro-
scopic level PML bodies devoid of proteasomes appear as
spheroid aggregates, whereas PML bodies containing pro-
teasomes have the characteristic shell-like or doughnut-
shaped structure (Lallemand-Breitenbach et al., 2001).
Clastosomes Are Distinct from Proteasome-
containing Nuclear Inclusions
In addition to clastosomes, some cells contain nuclear inclu-
sions intensely labeled by anti-proteasome and anti-ubiq-
uitin antibodies. Nuclear inclusions are very diverse in ap-
Figure 6. Adenovirus E1A oncoproteins localize in
proteasome-enriched domains and stimulate their
assembly. HeLa cells transiently transfected with
plasmid pE1A, which expresses adenovirus E1A
proteins, were double-labeled with anti-E1A anti-
body M73 (green staining) and either anti-19S pro-
teasome (B and C, red staining) or anti-ubiquitin
antibodies (E and F, red staining). (C and F) Overlay
of red and green images; colocalization produces a
yellowish color. Note that in some cases the E1A
proteins occupy only a fraction of the ubiquitin-
labeled structures (F, arrow). In E, the arrow indi-
cates a domain enriched in ubiquitin-conjugates but
devoid of E1A. Bar, 10 m. (G) Proportion of trans-
fected cells containing proteasome-enriched do-
mains and the number of bodies per cell were esti-
mated in a total of 300 randomly selected cells. The
graph depicts means  SEs.
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pearance from nuclear bodies and may consist of
amorphous, filamentous, or membranous material (Mon-
eron and Bernhard, 1969). In particular, degenerative dis-
eases are often associated with the presence of intranuclear
inclusions formed by deposits of aggregated protein in af-
fected neurons and muscle (Galvão et al., 2001; Orr, 2001).
Although these deposits are highly enriched in ubiquity-
lated proteins and components of the proteasome, they are
structurally distinct from nuclear bodies and hence they
should not be confused with clastosomes. Recent evidence
suggests that proteasomes are recruited to these abnormal
protein aggregates but because the substrate proteins are
tangled into a clump they cannot be efficiently degraded. As
a result, the proteasome possibly remains hold onto its prey
and consequently fails to degrade the normal protein targets
that are constantly being produced in the cell (Bence et al.,
2001).
To experimentally address whether nonphysiological de-
posits of aggregated and ubiquitylated proteins can recruit
proteasomes onto intranuclear inclusions, we analyzed the
distribution of proteasomes in HeLa cells overexpressing the
transcription factor c-Jun. c-Jun is a short-lived protein de-
graded in the nucleus by the ubiquitin–proteasome pathway
(Treier et al., 1994). The protein contains a 27-amino acid
segment, the  domain, which is required for efficient ubiq-
uitination. When the  domain is deleted, c-Jun is neither
ubiquitinated nor degraded (Treier et al., 1994). The onco-
genic retroviral counterpart of c-Jun, v-Jun, lacks the  do-
main and is not ubiquitinated in vivo. Consequently, v-Jun
escapes the mechanism of down-regulation by degradation
and the resulting increased stability of the protein most
likely contributes to its oncogenicity (Treier et al., 1994).
The overexpressed c-Jun protein forms deposits at the
periphery of nucleoli, which are labeled by anti-proteasome
antibodies. Viewed with the electron microscope, c-Jun and
components of the proteasome are detected in amorphous
aggregates that form tangles around nucleoli (Figure 9,
A–C). Discrete spheroidal or doughnut-shaped structures
containing the exogenously expressed protein are not ob-
served, indicating that overexpressed c-Jun does not assem-
ble into clastosomes. After treatment with proteasome in-
hibitors, c-Jun is still detected over the tangles of amorphous
aggregates (Figure 9C), but labeling of these structures by
anti-proteasome antibodies is greatly reduced (Figure 9B).
This suggests that in the presence of inhibitors the protea-
some is no longer recruited to the c-Jun protein aggregates.
We next examined the distribution of proteasomes in HeLa
cells overexpressing a deletion mutant of c-Jun lacking the 
domain (c-Jun ) and v-Jun. The double-labeling experi-
ments depicted in Figure 9, D–I, show that both c-Jun  and
v-Jun form aggregates in the nucleus that fail to recruit the
proteasome. Overexpression of unrelated control proteins
produced intranuclear aggregates that failed to recruit pro-
teasomes (our unpublished data).
In conclusion, we propose the following model for distri-
bution of proteasomes in the mammalian cell nucleus. All
cells contain 19S and 20S proteasomes spread throughout
the nucleoplasm. When there is a high demand for protea-
some-dependent proteolysis, the excessive protein sub-
strates associated with components of the ubiquitin–protea-
some pathway queue up for degradation forming a transient
and conserved structure, the clastosome. Once formed, clas-
tosomes recruit more proteins targeted for degradation, thus
enhancing the availability of substrates for the proteolytic
machine. Under certain pathological or nonphysiological
conditions (for example, overexpression), abnormal protein
aggregates form in the nucleus. In contrast to the conserved
doughnut profile of clastosomes, abnormal deposits of ag-
gregated proteins tend to be amorphous and very irregu-
larly shaped. Proteasomes are recruited and possibly
Figure 7. Electron microscopy re-
veals that proteasome-domains corre-
spond to complex nuclear bodies. Ul-
trathin sections from primary Schwann
cells were immunogold-labeled with
antibodies directed against 20S protea-
somes (A, 5-nm gold particles), 19S
proteasomes (B, 10-nm gold particles),
ubiquitin (C, 10-nm gold particles),
and c-Jun (D, 10-nm gold particles).
Bar, 0.1 m.
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trapped within these clumps whenever the aggregates con-
tain proteins recognized by the ubiquitination system.
DISCUSSION
In the nucleus of higher eukaryotes, the majority of short-
lived proteins are degraded via the ubiquitin–proteasome
pathway (Rock et al., 1994). In contrast with the extensive
and detailed knowledge on the structure and enzymatic
activity of the proteasome, current understanding of its spa-
tial organization in vivo is lagging behind. Herein, we show
that the mammalian cell nucleus contains a specific and
conserved domain enriched in proteasomes, which we refer
to as the clastosome. The clastosome concentrates 20S and
19S proteasomes, ubiquitin-conjugates and molecular chap-
erones Hsp70/Hsc70, as well as protein substrates of the
proteasome such as c-Fos, c-Jun, PML, and adenoviral E1A
proteins. Clastosomes are dynamic structures: they form in
response to stimuli that activate proteasome-dependent pro-
teolysis and they disappear when proteasome function is
inhibited. This suggests that proteasome-dependent prote-
olysis is taking place in clastosomes.
When viewed at the electron microscope, clastosomes
correspond to nuclear bodies. These structures were first
described by De Thé et al. (1960), and since then, numer-
ous electron microscopy studies reported the observation
of nuclear bodies in a variety of cell types (Bouteille et al.,
1967, 1974; Padykula and Clark 1981; Brasch et al., 1989).
On the basis of their structure, nuclear bodies have been
classified as either simple or complex (Bouteille et al.,
1974). The simple nuclear bodies are small (0.2– 0.5 m)
and finely fibrillar, whereas the complex nuclear bodies
are larger (0.2–1.2 m) and enveloped by a peripheral
capsule, which gives them a doughnut-shaped appear-
ance. Based on the data presented herein we propose that
the doughnut-shaped complex nuclear bodies correspond
to clastosomes.
Early electron microscopic studies showed that complex nu-
clear bodies are normally scarce, but their number increases
under certain conditions such as viral infection and hormonal
stimulation (Padykula and Clark, 1981; Padykula et al., 1981;
Brasch et al., 1989; Brasch and Ochs, 1992). Accordingly, we
show herein that clastosomes are absent or scarce in normal
cells, indicating that clastosomes are not essential for protea-
some function. Under normal conditions misfolded, unas-
sembled, or damaged proteins are rapidly and efficiently de-
graded by cellular proteasomes. This is probably the reason
why clastosomes are not normally detected. In the presence of
elevated levels of proteins targeted for proteasome-dependent
degradation (for example, in response to viral infection, hor-
monal stimulation, or stress) these may transiently queue up
for proteolysis giving rise to clastosomes. Once formed, clasto-
somes may act by recruiting additional proteins targeted to the
proteasome, thus enhancing the local availability of proteolytic
machines for substrate degradation.
Figure 8. PML protein is present in clastosomes. HeLa cells were double-labeled with anti-PML antibody (green staining) and either
anti-20S proteasome (A and C, red staining) or anti-ubiquitin antibodies (D and F, red staining). (C and F) Overlay of red and green images;
colocalization produces a yellowish color. Note that PML occupies only a fraction of large clastosomes (C and F, arrow). The arrow in B points
to a PML body that does not concentrate proteasomes. In D, the arrow points to a clastosome that contains little, if any, PML. Bar, 10 m.
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